These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7056975)

  • 21. Osteoporosis.
    Davies R; Saha S
    Am Fam Physician; 1985 Nov; 32(5):107-14. PubMed ID: 4061240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of bone mass in postmenopausal women.
    Aloia JF; Vaswani AN; Yeh JK; Ross P; Ellis K; Cohn SH
    Arch Intern Med; 1983 Sep; 143(9):1700-4. PubMed ID: 6615091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Variations in treatment of postmenopausal osteoporosis.
    Schwartz M; Anwah I; Levy RN
    Clin Orthop Relat Res; 1985; (192):180-4. PubMed ID: 3967420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study.
    Mazzuoli GF; Passeri M; Gennari C; Minisola S; Antonelli R; Valtorta C; Palummeri E; Cervellin GF; Gonnelli S; Francini G
    Calcif Tissue Int; 1986 Jan; 38(1):3-8. PubMed ID: 3079649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of nandrolone therapy on forearm bone mineral content in osteoporosis.
    Need AG; Horowitz M; Morris HA; Walker CJ; Nordin BE
    Clin Orthop Relat Res; 1987 Dec; (225):273-8. PubMed ID: 3677513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females.
    Christiansen C; Christensen MS; McNair P; Hagen C; Stocklund KE; Transbøl I
    Eur J Clin Invest; 1980 Aug; 10(4):273-9. PubMed ID: 6253303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effects on the bones of nandrolone decanoate therapy in postmenopausal osteoporosis].
    Gennari C; Agnusdei D; Gonnelli S
    Minerva Endocrinol; 1989; 14(1):69-74. PubMed ID: 2659955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The treatment of osteoporosis.
    Melick RA
    Med J Aust; 1986 Jun; 144(12):645-7. PubMed ID: 3520261
    [No Abstract]   [Full Text] [Related]  

  • 29. [Our experience in the treatment of post-menopausal osteoporosis (author's transl)].
    Rico Lenza H; Espinós Pérez D
    Med Clin (Barc); 1982 Apr; 78(8):322-5. PubMed ID: 7087600
    [No Abstract]   [Full Text] [Related]  

  • 30. Thiazide diuretics and bone mineral content in postmenopausal women.
    Adland-Davenport P; McKenzie MW; Notelovitz M; McKenzie LC; Pendergast JF
    Am J Obstet Gynecol; 1985 Jul; 152(6 Pt 1):630-4. PubMed ID: 4025422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical study on bone mineral mass in metabolic bone disorders--I-125 photon absorptiometry].
    Kishimoto H
    Nihon Seikeigeka Gakkai Zasshi; 1983 Nov; 57(11):1699-715. PubMed ID: 6676388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New approaches to the problems of osteoporosis.
    Nordin BE; Need AG; Morris HA; Horowitz M
    Clin Orthop Relat Res; 1985 Nov; (200):181-97. PubMed ID: 3905110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An appraisal of the role of estrogens in the treatment of postmenopausal osteoporosis.
    Chesnut CH
    J Am Geriatr Soc; 1984 Aug; 32(8):604-8. PubMed ID: 6747171
    [No Abstract]   [Full Text] [Related]  

  • 34. Total body bone mineral and lean body mass by dual-photon absorptiometry. III. Comparison with trunk calcium by neutron activation analysis.
    Mazess RB; Peppler WW; Harrison JE; McNeill KG
    Calcif Tissue Int; 1981; 33(4):365-8. PubMed ID: 6794874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 7. Fluoride therapy for osteoporosis.
    Murray TM; Ste-Marie LG
    CMAJ; 1996 Oct; 155(7):949-54. PubMed ID: 8837545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate.
    Ringe JD; Kipshoven C; Cöster A; Umbach R
    Osteoporos Int; 1999; 9(2):171-8. PubMed ID: 10367046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postmenopausal osteoporosis.
    Silverberg SJ; Lindsay R
    Med Clin North Am; 1987 Jan; 71(1):41-57. PubMed ID: 3543542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment.
    Civitelli R; Gonnelli S; Zacchei F; Bigazzi S; Vattimo A; Avioli LV; Gennari C
    J Clin Invest; 1988 Oct; 82(4):1268-74. PubMed ID: 3262626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The minimum effective dose of estrogen for prevention of postmenopausal bone loss.
    Lindsay R; Hart DM; Clark DM
    Obstet Gynecol; 1984 Jun; 63(6):759-63. PubMed ID: 6374537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of methandrostenolone on postmenopausal bone wasting as assessed by changes in total bone mineral mass.
    Chesnut CH; Nelp WB; Baylink DJ; Denney JD
    Metabolism; 1977 Mar; 26(3):267-77. PubMed ID: 319322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.